The U-PLEX platform makes it easy to create multiplex immunoassays. Using two simple tools - a 10-spot U-PLEX plate and unique Linkers - you can build multiplex panels for any combination of analytes. The analytes in the U-PLEX menu are organized into U-PLEX Groups. Analytes within the same U-PLEX Group have been tested for multiplex compatibility and can be combined in panels with confidence.
The U-PLEX Metabolic Group 1 (rat) contains 12 biomarkers (Table 1) related to the metabolic syndrome and other disorders. This U-PLEX Group can be ordered as a full panel (12 markers) or as one or more smaller panels that are subsets of the full panel. The full panel is available as a catalog product K15308K. Ordering any subset of assays from the U-PLEX Metabolic Group 1 (rat) is simple and can be done online with MSD’s
U-PLEX Assay Designer.
Analyte | LLOD - ULOD | units |
BDNF | 0.72 - 2,000 | pg/mL |
C-Peptide | 220 - 125,000 | pg/mL |
FGF-21 | 2.8 - 8,230 | pg/mL |
Ghrelin (active) | 13 - 7,160 | pg/mL |
Ghrelin (total) | 1.7 - 2,710 | pg/mL |
GLP-1 (active) | 0.14 - 57 | pM |
GLP-1 (inactive) | 1.5 - 576 | pM |
GLP-1 (total) | 0.59 - 576 | pM |
Glucagon | 0.13 - 156 | pM |
Insulin | 3.0 - 5,500 | μIU/mL |
Leptin | 11 - 50,000 | pg/mL |
PYY (total) | 1.1 - 4,000 | pg/mL |
-
-
Specifications
-
-
-
Documentation
-
References
Application(s)
|
|
Metabolic
|
|
Species
|
|
Rat
|
|
U-PLEX Group Compatibility
|
|
Metabolic Group 1
|
|
Sample Type
|
|
Cell Culture Media, EDTA Plasma, P800 Plasma, Serum
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Condition
|
|
Multi-Component
|
|
Product Inserts
|
|
|
Datasheets
|
|
View More
|
Product Highlights
|
|
|
Title
|
Journal
|
Year
|
|
Leptin levels are associated with multiple sclerosis risk
|
|
|
|
Genetic Deletion and Pharmacological Inhibition of Phosphodiesterase 10A Protects Mice From Diet-Induced Obesity and Insulin Resistance.
|
|
|
|
A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study.
|
|
|
|
Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice.
|
|
|
|
Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
|
|
|
|
View All
|
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters